Sharad Singhal is a research professor in the Department of Medical Oncology & Therapeutics Research at Beckman Research Institute of City of Hope, and an affiliate full member of City of Hope’s comprehensive cancer center and Developmental Cancer Therapeutics Program in Duarte, California. He received his B.Sc. in biology (1982) and M.Sc. in chemistry (1984) from Agra University in India, and his Ph.D. in biochemistry (1989) from Central Drug Research Institute in Lucknow, India. He received a Council of Scientific and Industrial Research fellowship during his Ph.D. He did his postdoctoral training at the University of Texas Medical Branch in Galveston, Texas (1989–1993). His research interests are in glutathione metabolism and its role in stress-defense, carcinogenesis, drug-resistance, radiation-resistance and cell-signaling mechanisms. The focus of his current research is the development of natural compounds that broadly target cancer-specific signaling networks into the next generation of cancer preventive and therapeutic drugs that have the advantageous side effect of lowering insulin-resistance. He has successfully employed a highly effective in-silico signaling model based on the mercapturic acid pathway, which has already yielded three novel, natural source, lead compounds with very high efficacy in tumors of prostate, breast, renal, and neuroblastoma.